Anixa Biosciences is trading at $2.86, down 6.38% in pre-market on November 4 versus the November 3 close of $3.06; no clear company announcement explaining the decline was found.
- The latest company press release located was dated October 5; its ovarian cancer trial update was October 26.
- A report said Wall Street Zen cut its rating from hold to sell, but did not establish this as the cause.
- Broader U.S. futures were higher, so a market-wide same-direction explanation is not evident.